

J.Henderson GI.Life Sciences F.I2 H / IE00BMXMTZ48 / A3DDC7 / Janus Henderson Inv.

Last 05/20/2024 ¹	Region	Branch	Type of yield	Type
12.07 HKD	Worldwide	Sector Health / Pharma	reinvestment	Equity Fund



Risk key figures

SRI	1	2	3	4	5	6	7
Mountain-View Funds Rating ²							EDA ³
							76

Yearly Performance

2023	+6.35%
2022	-3.39%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	2.00%	Minimum investment	HKD 8,000,000.00
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Health / Pharma	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Ireland	Redemption charge	0.00%	Performance fee	0.00%
Tranch volume	(05/20/2024) USD 0.028 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(05/20/2024) USD 4,036.54 mill.	Dividends		Investment company	
Launch date	3/30/2021	Janus Henderson Inv. 201 Bishopsgate, EC2M 3AE, London United Kingdom www.janushenderson.com/			
KESr report funds	No				
Business year start	01.01.				
Sustainability type	-				
Fund manager	Andy Acker, Daniel Lyons				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+5.41%	+18.45%	+7.58%	+9.73%	+26.39%	+17.41%	-	+20.70%
Performance p.a.	-	-	-	+9.76%	+12.40%	+5.49%	-	+6.25%
Sharpe ratio	9.82	2.87	1.46	0.47	0.58	0.11	-	0.16
Volatility	9.68%	12.86%	11.83%	12.56%	14.84%	15.39%	0.00%	15.29%
Worst month	-	-4.84%	-4.84%	-6.43%	-6.43%	-8.88%	0.00%	-8.88%
Best month	-	7.37%	7.37%	7.37%	8.37%	8.37%	0.00%	8.37%
Maximum loss	-0.76%	-7.49%	-7.49%	-12.65%	-13.27%	-22.05%	0.00%	-

Distribution permission

Austria, Germany, Switzerland

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.
² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)


J.Henderson GI.Life Sciences F.I2 H / IE00BMXMTZ48 / A3DDC7 / Janus Henderson Inv.

Investment goal


The Fund seeks long - term growth of capital by investing primarily in life - science equity securities of companies located anywhere in the world and selected for their growth potential.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

